Fmr LLC Purchases 46,110 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fmr LLC boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,988,389 shares of the biotechnology company’s stock after acquiring an additional 46,110 shares during the period. Fmr LLC’s holdings in BioCryst Pharmaceuticals were worth $15,112,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after acquiring an additional 86,571 shares during the period. Fisher Asset Management LLC raised its stake in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the period. Alpha DNA Investment Management LLC bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter worth approximately $448,000. Algert Global LLC raised its stake in BioCryst Pharmaceuticals by 46.2% during the 3rd quarter. Algert Global LLC now owns 516,209 shares of the biotechnology company’s stock worth $3,923,000 after acquiring an additional 163,076 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in BioCryst Pharmaceuticals by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company’s stock worth $14,349,000 after acquiring an additional 102,860 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $7.93 on Wednesday. The firm has a fifty day moving average price of $7.60 and a 200 day moving average price of $7.37. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The firm has a market cap of $1.64 billion, a PE ratio of -13.00 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same period last year, the business posted ($0.19) earnings per share. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Analyst Ratings Changes

BCRX has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.